Page 131 - Drug Class Review
P. 131
Drug Effectiveness Review Project
Raskind MA, Peskind ER, Wessel T, Yuan W, and the Galantamine USA-1 Study Group.
Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S. 2000;
Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. 2001;
Group. 2000; Wilcock GK, Lilienfeld S, Gaens E on behalf of the Galantamine International-1 Study Wilkinson D, Murray J, in collaboration with the Galantamine Research Group. 2001; 1989 – November 2004 Randomized, double blind, placebo controlled trials with donepezil, rivastigmine, or galantamine in patients with Alzheimer’s disease; Excluded trials that did not examine clinical outcomes or focused on vascular dementia; Excluded head to head comparisons in the analysis Page 96 of 205
2000; NR
Final Report Update 1 TIME PERIOD COVERED: CHARACTERISTICS OF INCLUDED STUDIES: CHARACTERISTICS OF INCLUDED POPULATIONS: Alzheimer's Drugs
